Immunohematology Market By Product (Analyzers and Systems, Reagents) , By Application (Blood-related Diseases, HIV, Others) By End User (Hospitals, Diagnostic Laboratories, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The global immunohematology market was valued at $1.9 billion in 2023, and is projected to reach $3.0 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.
Immunohematology, also known as blood banking or transfusion medicine, is a specialized branch of laboratory medicine that focuses on the study of blood groups and antibodies associated with blood transfusion. It involves the identification and characterization of blood group antigens on the surface of red blood cells and the corresponding antibodies present in plasma. The main goal of immunohematology is to ensure safe and compatible blood transfusions by matching the blood type of the donor with that of the recipient to prevent adverse reactions. This field plays a crucial role in transfusion therapy, organ transplantation, and managing various hematologic disorders.
The growth of the global immunohematology market is driven by rise in the prevalence of chronic diseases and surge in the number of surgical procedures, which have significantly boosted the need for accurate blood typing and cross-matching, which are crucial for safe transfusion practices. In addition, aging population has led to a higher incidence of conditions such as anemia and leukemia, further escalating the demand for immunohematology products. Moreover, rise in awareness and stringent regulations regarding blood safety and donor compatibility are contributing to the expansion of immunohematology market growth.
However, high cost associated with advanced immunohematology instruments and reagents, which can limit their adoption, especially in developing regions with limited healthcare budgets. On the other hand, adoption of automated and digital blood testing platforms offers significant potential for improving diagnostic accuracy and efficiency, catering to the growing demand for rapid and reliable blood typing and cross-matching. For instance, in May 2023, Bio-Rad Laboratories, Inc. announced the launch of the IH-500TM NEXT System, a fully automated system for ID-Cards. The IH-500 NEXT System is used with Bio-Rad's ID-Cards, offering a broad portfolio for both routine testing (type and screen) and specialized testing, including single antigen determination and newborn screening.
Segmentation OverviewThe global immunohematology market is segmented into product, application, end user, and region. Depending on the product, the market is categorized into analyzers & systems and reagents. By application, it is classified into blood-related diseases, HIV, and others. According to end user, the market is divided into hospitals, diagnostic Laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key FindingsBy product, the reagents segment held the highest share in the market in 2023.
Depending on the application, the blood-related diseases segment accounted for the maximum market share in 2023.
According to end user, the hospitals segment was the largest shareholder in 2023.
Region wise, North America dominated the global immunohematology market in 2023.
Competitive ScenarioThe major players operating in the immunohematology market include Bio-Rad Laboratories, Inc, Werfen, Grifols, S.A., Danaher Corporation, Siemens, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche Ltd, and Cardinal Health. These players have adopted several tactics such as product advancement & diversification, mergers & acquisitions, partnerships, collaborations, and advertising to strengthen their position in the competitive environment.
Key Market SegmentsBy ProductAnalyzers and Systems
Reagents
By ApplicationBlood-related Diseases
HIV
Others
By End UserHospitals
Diagnostic Laboratories
Others
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Bio-Rad Laboratories, Inc
Werfen
Grifols, S.A.
Danaher Corporation
Siemens
Thermo Fisher Scientific Inc.
Abbott Laboratories
Merck KGaA
F. Hoffmann-La Roche Ltd
Cardinal Health